Long-term follow-up of adults with antiphospholipid syndrome
Official title: Follow-up Cohort of Patients With Antiphospholipid Syndrome
Run by University Hospital, Rouen · NCT07178925 · Data updated 2026-11-12
This project will test how often blood clots come back and which factors affect recurrence in adults with antiphospholipid syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University Hospital, Rouen Academic / other |
| Locations | 1 site (Rouen) |
| Status | Recruiting |
| Started | October 16, 2019 |
| Main results expected | October 16, 2027 |
| Study ends | October 16, 2032 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07178925 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with antiphospholipid syndrome confirmed by the 2006 Sydney classification are the intended participants.
✕Probably not a fit
People under 18, over 75, or without antiphospholipid syndrome by the 2006 Sydney criteria are not eligible and therefore would not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center cohort combines retrospective chart review with prospective follow-up of adults meeting the 2006 Sydney criteria for antiphospholipid syndrome at the University Hospital of Rouen. The primary objective is to determine the rate of thrombotic recurrence (arterial and venous) in this population at our center. Secondary objectives include identifying clinical and treatment-related risk factors for recurrence, evaluating long-term treatment safety, and documenting overall morbidity and mortality. Results will be used to refine estimates of recurrence risk and to inform sample-size planning for future therapeutic trials.
Why it matters
Potential benefit: If successful, this could provide more accurate recurrence rates and identify risk factors that help guide treatment decisions and the design of future trials.
How similar studies have gone: Previous observational cohorts have reported recurrence rates around 5% per year, but those studies are older and heterogeneous, so findings are only partially consistent and not definitive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients over 18 years of age and under 75 years of age * Antiphospholipid syndrome meeting the 2006 Sydney classification Exclusion Criteria: * Patients under the age of 75 or over * Syndrome not meeting the 2006 Sydney classification
Where it's running
-
University hospital of Rouen
Rouen, France Recruiting
Study contacts
- Study coordinator: Sébastien SM MIRANDA, Doctor
- Email: Sebastien.Miranda@chu-rouen.fr
- Phone: 02 32 88 90 01
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Anifrolumab for adults with primary antiphospholipid syndrome
This phase II pilot tests whether weekly subcutaneous anifrolumab is safe and tolerable in adults with primary antiphospholipid syndrome while they continue their standard care.
-
DOACs versus VKAs to prevent repeat clots in low‑risk antiphospholipid syndrome
This project will see if direct oral anticoagulants (DOACs) work as well and are as safe as vitamin K antagonists (VKAs) to prevent repeat venous clots in adults with low‑risk thrombotic antiphospholipid syndrome.
-
YTS109 cell therapy for relapsed/refractory autoimmune diseases
This trial will try a single infusion of YTS109 immune cells to see if they are safe and help adults aged 18–65 with relapsed or refractory autoimmune diseases such as lupus, Sjogren’s syndrome, inflammatory myopathy, or ANCA-associated vasculitis.
-
YTS109 cell therapy for relapsed or refractory autoimmune diseases
This trial will try a single infusion of YTS109 cells to see if they are safe and help adults (18–65) with relapsing or refractory autoimmune diseases such as SLE, lupus nephritis, systemic sclerosis, inflammatory myopathy, or ANCA-associated vasculitis.
-
YTS109 cell therapy for relapsed or refractory systemic autoimmune diseases
This trial will try a single infusion of YTS109 cells to see if it's safe and helps adults 18–65 with relapsed or refractory systemic autoimmune diseases such as SLE, systemic sclerosis, inflammatory myopathies, ANCA-associated vasculitis, or antiphospholipid syndrome.
-
Evaluating Belimumab's effect on antibody levels in patients with Antiphospholipid Syndrome
This study is testing if adding Belimumab to standard treatment can lower antibody levels in people with Antiphospholipid Syndrome.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.